Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Spondyloarthritis family · A closer look at PsA

PsA: persistent pain and an insufficient treatment response

How to investigate symptoms that remain, distinguish different kinds of treatment difficulty and plan the next step.

Olga Goodman, MD · Sources checked 27 September 2026

Chapter 8 of 21

The essentials

Persistent symptoms deserve attention. They may reflect active inflammation, another pain mechanism, treatment interruption or several problems together. The explanation determines what is likely to help.

Start with what changed

Note when the problem began, which areas are affected, swelling, stiffness, function and any fever or new illness. Was there initial improvement followed by a relapse, or no useful improvement at all? Bring a short timeline of medicines, dose changes, interruptions and why each treatment ended.

New severe symptoms should not automatically be called a PsA flare. A hot swollen joint, fever or acute eye symptoms need prompt assessment; chest pain, sudden breathlessness or stroke-like symptoms require emergency help.

RV-PSA-04 · Aim for the Bullseye — Free after registration →

Is there ongoing inflammation?

The clinician combines examination, the distribution of symptoms, laboratory findings and selected imaging when it can answer a specific question. Normal inflammatory markers do not settle the issue. Nor does pain alone establish inflammation in every painful area. 3

If inflammation remains active, the team reviews whether the treatment fits the affected domains, whether exposure was adequate and what change is justified. A strong response in skin can coexist with insufficient joint control.

Other contributors to pain are real

Previous joint damage, osteoarthritis, mechanical tendon problems and nerve-related pain may coexist with PsA. Widespread pain sensitivity, poor sleep, fatigue and mood difficulties can also amplify the burden. More than one mechanism may operate at once. 3, 13, 14

Addressing these contributors can involve rehabilitation, load adjustment, sleep care or a separate pain strategy. This does not invalidate the PsA diagnosis or imply that symptoms are imagined. Conversely, identifying another contributor should not prevent treatment of demonstrable active inflammation.

What does “the treatment did not work” mean?

Use a precise description rather than treating every discontinued prescription as the same failure. The distinctions below guide the review; none is a verdict that effective care is impossible.

What does “the treatment did not work” mean?
PatternWhat to clarify
Primary insufficient responseWas there no meaningful benefit after an adequate trial? Were the diagnosis, dose and treatment target appropriate?
Loss of responseWhat improved first, what returned, and were there interruptions or new health problems?
IntoleranceDid adverse effects prevent a fair trial or make otherwise useful treatment unacceptable?
Interrupted access or useWas enough treatment actually received? Cost, supply and practical obstacles need solutions.
Partial response across domainsWhich areas improved and which remain active? Skin, joints and spine do not always move together.

Prepare a useful follow-up

For each previous medicine record: start and stop dates, approximate dose and route, benefit in each area, adverse effects, missed doses and the reason for stopping. Note access or injection problems without embarrassment. Those details change the interpretation.

Agree on the next clinical question, what will answer it, who will act and when. If multiple trials have not helped, a fresh review of diagnosis, objective inflammation and overlapping conditions may be more useful than repeating the same assumption.

A plan can address several problems at once

The next plan may include a change in disease-modifying treatment, rehabilitation, pain management, attention to sleep or another condition, and help obtaining medicines. Choose a few concrete goals and a review date. Do not increase, combine or stop targeted medicines on the basis of this chapter alone.

Go deeper

Difficult to manage is not the same as treatment refractory

EULAR and GRAPPA published separate consensus frameworks in 2025–2026. They distinguish broad difficulty controlling disease from a narrower inflammatory refractory state. These are not interchangeable labels or a self-assessment calculator. 13, 14

The full definitions also consider continuing problematic symptoms and alternative explanations; a medicine count alone is insufficient. Both frameworks need further validation. Their practical message for a patient is to ask what is driving the difficulty, rather than to accept a label suggesting that nothing more can be done.

Difficult to manage is not the same as treatment refractory
FrameworkDistinction
EULAR: D2M / TR PsABroad management difficulty versus a subgroup with objective inflammation; treatment history includes ≥2 biologic/targeted synthetic drugs with ≥2 mechanisms. 13
GRAPPA: C2M / TR PsAC2M starts after ≥1 biologic/targeted synthetic drug; TR requires ≥3 distinct mechanisms, including ≥2 such drugs, plus objective inflammation and other criteria. 14

Questions for your visit

  1. What evidence shows active inflammation now?
  2. Which other causes could contribute to my symptoms?
  3. What exactly prevented previous treatments from succeeding?
  4. What is the next question, action and review date?

When to seek urgent help

A painful red eye, light sensitivity or a sudden change in vision needs urgent assessment. A newly hot, swollen joint, especially with fever or feeling unwell, also needs prompt assessment.

Sources & evidence notes

Sources checked 27 September 2026

Drug approvals and availability vary by country. Regulatory updates are identified separately from older recommendations.

  1. NIAMS. Psoriatic arthritis: diagnosis, treatment and steps to take.
  2. Marzo-Ortega H et al. EULAR definitions for difficult-to-manage and treatment-refractory PsA. Ann Rheum Dis. 2026;85:61–74. Online 2025.
  3. Ribeiro AL et al. GRAPPA definitions of complex-to-manage and treatment-refractory PsA. Nat Rev Rheumatol. 2026;22:132–144. Online 2025.

Educational information for patients and caregivers. This personal publication is not the clinic portal and does not provide individual diagnosis or treatment. Discuss medication changes with your own care team.

© 2026 Olga Goodman, MD · A RheumaView publication. Copying without attribution prohibited.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: PsoriasisPsoriatic arthritisSpondyloarthritis